- Home
- CNMD vs MYGN Comparison
CNMD vs MYGN Comparison
Compare CNMD & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- MYGN
- Stock Information
- Founded
- CNMD 1970
- MYGN 1991
- Country
- CNMD United States
- MYGN United States
- Employees
- CNMD N/A
- MYGN N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNMD Health Care
- MYGN Health Care
- Exchange
- CNMD Nasdaq
- MYGN Nasdaq
- Market Cap
- CNMD 2.2B
- MYGN 2.0B
- IPO Year
- CNMD 1987
- MYGN 1995
- Fundamental
- Price
- CNMD $68.65
- MYGN $13.36
- Analyst Decision
- CNMD Buy
- MYGN Hold
- Analyst Count
- CNMD 6
- MYGN 12
- Target Price
- CNMD $82.83
- MYGN $23.92
- AVG Volume (30 Days)
- CNMD 428.8K
- MYGN 1.1M
- Earning Date
- CNMD 01-29-2025
- MYGN 11-07-2024
- Dividend Yield
- CNMD 1.17%
- MYGN N/A
- EPS Growth
- CNMD 127.53
- MYGN N/A
- EPS
- CNMD 4.22
- MYGN N/A
- Revenue
- CNMD $1,288,116,000.00
- MYGN $823,600,000.00
- Revenue This Year
- CNMD $6.69
- MYGN $13.82
- Revenue Next Year
- CNMD $7.53
- MYGN $4.59
- P/E Ratio
- CNMD $16.26
- MYGN N/A
- Revenue Growth
- CNMD 10.23
- MYGN 12.15
- 52 Week Low
- CNMD $61.05
- MYGN $12.87
- 52 Week High
- CNMD $114.80
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CNMD 39.61
- MYGN 26.22
- Support Level
- CNMD $71.28
- MYGN $12.87
- Resistance Level
- CNMD $72.49
- MYGN $15.44
- Average True Range (ATR)
- CNMD 2.78
- MYGN 0.84
- MACD
- CNMD -0.72
- MYGN -0.02
- Stochastic Oscillator
- CNMD 6.11
- MYGN 12.37
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.